Radium 223 Dichloride (Xofigo)®

Common name: Radium 223 Dichloride
Brand name: Xofigo®
 

What is Radium 223 Dichloride?


Radium 223 Dichloride is a radiopharmaceutical that is used to treat patients with castration-resistant prostate cancer which has spread to the bones, but has not spread to other organs in the body.
 

How is Radium 223 Dichloride administered?


Radium 223 Dichloride is administered by injection.
 

What are possible side effects of this treatment?


Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are the most common side effects experienced by those who received radium 223 dichloride. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Nausea
  • Diarrhea
  • Vomiting
  • Swelling of the arms or legs
  • Low blood cell count
 

Is Radium 223 Dichloride covered in my province or territory?

Radium 223 Dichloride is covered by provincial drug programs in:
 
  • British Columbia (special authorization)
  • Manitoba
  • Ontario
  • Québec
  • Saskatchewan
 
Radium 223 Dichloride is not covered by provincial drug programs in:
 
  • Alberta
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Prince Edward Island
  • Nunavut
  • Northwest Territories
  • Yukon
Last Reviewed: April 2018

Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More

Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More


Click here for news archive